The company expects this quarter's adjusted earnings to be flat compared with the previous quarter's $1.04 per share. That would be a 9% increase year over year, but Genzyme is a high-growth company where quarter-over-quarter measurements are important.
The flat growth of earnings is coming from supply constraints from Myozyme, its treatment for a rare disorder called Pompe. Genzyme is guiding for 50% sales growth this year, but first it has to get American and European regulators to sign off on larger manufacturing scales. It's expecting a decision by Feb. 28 from the Food and Drug Administration and in April from the European regulators.
Once it does step on the gas, investors should get a nice ride in the form of 13% to 17% revenue growth this year. That's pretty impressive, considering that it's having to fight through a major headwind from currency movements just like its large pharmaceutical counterparts, Johnson & Johnson
Genzyme, BioMarin Pharmaceuticals
BioMarin is a Motley Fool Rule Breakers pick. The newsletter is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Johnson & Johnson is a selection of the Income Investor newsletter. The Fool has a disclosure policy.